Development of ABT-806i, a Kit-formulated 111In-ABT-806 antibody directed to EGFR for tumor imaging
Edward B. Reilly(AbbVie (United States)), Greg Buchanan(AbbVie (United States)), Thomas Merdan(AbbVie (United States)), John E. Harlan(Abbott (United Kingdom)), Debra C. Ferguson(AbbVie (United States)), Jonathan A. Meulbroek(Abbott Fund), Todd Cole(AbbVie (United States)), Martin J. Voorbach(AbbVie (United States)), Andrew C. Phillips(AbbVie (United States))
Journal of Nuclear Medicine
May 1, 2013
Cited by 0
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Genetic and molecular analysis of a Caenorhabditis elegans beta-tubulin that conveys benzimidazole sensitivity.
|The Journal of Cell Biology|1989|268
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
|Clinical Cancer Research|2008|211
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
|Molecular Cancer Therapeutics|2016|185